Skip to main content
. 2020 Nov 6;8(2):e001355. doi: 10.1136/jitc-2020-001355

Figure 1.

Figure 1

Circulating NK and T cells in patients with STS. (A) Characteristics of the prospective STS cohort undergoing blood and tumor analysis. (B) Flow cytometry gating for analysis of peripheral blood with NK cells (CD56+CD3−), CD3+ T cells (CD56−CD3+), and CD8+ T cells (CD56−CD3+CD8+). (C) Distribution of absolute lymphocyte counts (ALCs) and lymphocyte subsets in the peripheral blood of all patients, and (D) comparison between patients experiencing no relapse (‘No Rel.’) or relapse (‘Relapse’) during follow-up. Circulating CD3+ T cells are significantly lower in patients experiencing relapse (1.3±0.3×103 cells/µL vs 0.6±0.2×103 cells/µL, p=0.025). Representative TIGIT and PD-1 flow cytometry and distribution of expression on (E, H) NK cells, (F, I) CD3+ T cells, and (G, J) CD8+ T cells. Mean±SEM. P values determined using the Mann-Whitney test. NK, natural killer; PD-1, programmed death 1; STS, soft tissue sarcoma.